Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 271
Filter
2.
Eur J Clin Nutr ; 66(8): 878-84, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22669332

ABSTRACT

BACKGROUND/OBJECTIVES: The antiestrogen, Raloxifene (Ral) is an effective breast cancer chemopreventive agent. Omega-3 fatty acids (n-3FA) may inhibit mammary carcinogenesis. On the basis of their mechanisms of action, we test the hypothesis that a combination of n-3FA and Ral may be superior in reducing select biomarkers of breast cancer risk in women. SUBJECTS/METHODS: Postmenopausal women at increased risk for breast cancer (breast density ≥ 25%) were randomized to: (1) no intervention; (2) Ral 60 mg; (3) Ral 30 mg; (4) n-3FA (Lovaza) 4 g and (5) Lovaza 4 g+Ral 30 mg for 2 years. Reduction in breast density is the primary end point of the study. We report preliminary data on feasibility, compliance and changes in secondary end points related to IGF-I signaling, estrogen metabolism, oxidative stress and inflammation in the first group of 46 women who completed 1 year of the study. RESULTS: All interventions were well tolerated with excellent compliance (96 ± 1% overall) by pill count and also supported by the expected rise in both serum n-3FA and n-3FA/Omega-6 fatty acids (n-6FA) ratio in women randomized to groups 4 and 5 (P<0.05). Lovaza decreased serum triglycerides and increased high-density lipoprotein (HDL) cholesterol compared with control (P<0.05 for both). Ral reduced serum IGF-1 in a dose-dependent manner (P<0.05) while Lovaza did not. Lovaza had no effect on IGF-1 or IGFBP-3. None of the other biomarkers were affected by our treatment. CONCLUSION: The combination of Lovaza and Ral is a feasible strategy that may be recommended in future breast cancer chemoprevention trials.


Subject(s)
Biomarkers/blood , Breast Neoplasms/prevention & control , Fatty Acids, Omega-3/administration & dosage , Feeding Behavior , Raloxifene Hydrochloride/administration & dosage , Adult , Aged , Biomarkers/urine , Breast Neoplasms/physiopathology , C-Reactive Protein/analysis , C-Reactive Protein/metabolism , Docosahexaenoic Acids , Dose-Response Relationship, Drug , Drug Combinations , Eicosapentaenoic Acid , Endpoint Determination , Estrogen Antagonists/administration & dosage , Fatty Acids, Omega-3/therapeutic use , Feasibility Studies , Female , Humans , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor I/metabolism , Linear Models , Lipid Peroxidation/drug effects , Middle Aged , Motor Activity , Oxidative Stress/drug effects , Postmenopause , Risk Factors , Selective Estrogen Receptor Modulators/administration & dosage , Signal Transduction
4.
Int J Sports Med ; 25(7): 496-501, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15459829

ABSTRACT

Resistance exercise has positive effects on bone mass, but little is known about the mechanisms by which this occurs. The purpose of this study was to determine if a single bout of moderate intensity resistance exercise alters biochemical markers of bone cell activity. Indices of bone turnover were measured in nine healthy, untrained men (21.9 +/- 1.2 yrs old), before and following a single 45 minute session of resistance exercise, and during a control trial. A cross-over design was used so that all participants performed both trials in random order. Blood samples were collected immediately before, immediately after, and at 1, 8, 24, and 48 hours post exercise and analyzed for bone-specific alkaline phosphatase (BAP), type I collagen propeptide (PICP), and type I collagen N-telopeptide (sNTX). Urine from the second morning void was collected over four days (day before, day of, and two days following exercise) and analyzed for type I collagen N-telopeptide (uNTX). Exercise resulted in a significant increase (p < 0.05) in the ratio of biochemical markers of bone formation to bone resorption eight hours post exercise, largely due to a decrease in sNTX. Markers return to baseline within 24 hrs. These data suggest that moderate intensity resistance training acutely reduces bone resorption, leading to a favorable change in overall bone turnover, for at least 8 hours post exercise in untrained young men. Further work is needed to determine if long-term benefits to bone strength follow with persistent training.


Subject(s)
Bone Remodeling/physiology , Bone and Bones/cytology , Exercise/physiology , Weight Lifting/physiology , Adult , Biomarkers/blood , Bone Density , Bone and Bones/physiology , Cross-Over Studies , Humans , Male , Weight-Bearing
5.
Ann Oncol ; 15(3): 455-9, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14998848

ABSTRACT

BACKGROUND: There is significant heterogeneity in survival of patients with metastatic breast cancer who have bone-only metastasis. We studied the correlation of serum N-telopeptide (NTx), a marker of bone resorption, and its correlation with clinical outcomes in patients with metastatic breast cancer with bone-only or bone plus soft tissue metastasis. PATIENTS AND METHODS: Serum was taken from 250 metastatic breast cancer patients with bone-only or bone plus soft tissue metastasis who participated in two similar randomized studies of second-line hormone therapy. An enzyme-linked immunosorbent assay specific for NTx of type I bone collagen was used to detect serum levels. RESULTS: Sixty patients (24%) had elevated serum NTx levels, using the mean + 2 standard deviations (26 nanomoles Bone Collagen Equivalents per liter) of healthy women as a cut-off. The median duration of clinical benefit was significantly shorter in the group with elevated serum NTx levels compared with the group that had normal serum NTx levels (P=0.0004). Time to progression (TTP) was also significantly shorter in the patients with elevated serum NTx at 139 days compared with 220 days (P=0.0006). Median survival was also significantly shorter in patients with elevated baseline serum NTx levels at 663 days compared with 941 days (P<0.0001). CONCLUSION: In this study, breast cancer patients with bone-only or bone plus soft tissue metastasis and elevated serum NTx levels have a shorter duration of clinical benefit, TTP and overall survival.


Subject(s)
Biomarkers, Tumor/blood , Bone Neoplasms/blood , Breast Neoplasms/blood , Collagen/blood , Peptides/blood , Soft Tissue Neoplasms/blood , Adult , Aged , Aged, 80 and over , Bone Neoplasms/secondary , Bone Resorption/blood , Breast Neoplasms/pathology , Collagen Type I , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Humans , Middle Aged , Prognosis , Soft Tissue Neoplasms/secondary , Survival Rate , Time Factors , Treatment Outcome
7.
Science ; 296(5574): 1836-8, 2002 Jun 07.
Article in English | MEDLINE | ID: mdl-12052950

ABSTRACT

The use of direct-write dip-pen nanolithography (DPN) to generate covalently anchored, nanoscale patterns of oligonucleotides on both metallic and insulating substrates is described. Modification of DNA with hexanethiol groups allowed patterning on gold, and oligonucleotides bearing 5'-terminal acrylamide groups could be patterned on derivatized silica. Feature sizes ranging from many micrometers to less than 100 nanometers were achieved, and the resulting patterns exhibited the sequence-specific binding properties of the DNA from which they were composed. The patterns can be used to direct the assembly of individual oligonucleotide-modified particles on a surface, and the deposition of multiple DNA sequences in a single array is demonstrated.


Subject(s)
DNA , Gold , Microscopy, Atomic Force , Nanotechnology , Oligodeoxyribonucleotides , Oxides , Silicon Compounds , Adsorption , DNA/chemistry , Humidity , Nucleic Acid Hybridization , Oligodeoxyribonucleotides/chemistry , Oligonucleotide Array Sequence Analysis , Organosilicon Compounds , Silanes , Sulfhydryl Compounds , Surface Properties , Temperature
9.
Child Dev ; 72(5): 1439-50, 2001.
Article in English | MEDLINE | ID: mdl-11699680

ABSTRACT

The objective of the present study was to determine the role of sex steroids in the development of self-perceived competence during adolescence. The Harter Self-Perception Scale was administered to 56 adolescents with delayed puberty who were receiving depo-testosterone (males) or conjugated estrogens (females) administered in 3-month blocks alternating with placebo. Treatment was given at three dose levels approximating early, middle, and late pubertal replacement levels. Hormone treatments had a significant positive effect for both males and females in one subscale domain--perceived job competence. Significant positive hormone effects were also obtained for perceptions of romantic appeal and close friendship in females and perception of athletic abilities in males. It can be inferred from the results of this study that the hormonal changes associated with sexual maturation have targeted influences on specific domains of self-perceived competence and that there are clear gender differences.


Subject(s)
Gonadal Steroid Hormones/therapeutic use , Hormone Replacement Therapy/psychology , Puberty, Delayed/psychology , Self Efficacy , Adolescent , Adult , Analysis of Variance , Child , Cross-Over Studies , Female , Humans , Male , Puberty, Delayed/drug therapy , Puberty, Delayed/etiology , Self-Assessment , Sex Characteristics
10.
Ann Clin Psychiatry ; 13(2): 75-80, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11534928

ABSTRACT

Andropause is a syndrome described in aging males, is composed of a constellation of physical, sexual, and emotional symptoms, and is thought to be related to declining concentrations of serum testosterone. Numerous studies of testosterone replacement therapy in elderly hypogonadal males have documented the physical benefits of such treatment, but have failed to assess cognition, psychological functioning, and quality of life. Male outpatients greater or equal to 55 years of age completed cognitive, psychological, sexual, and quality of life assessments. A serum sample was provided for bioavailable testosterone assay. The associations between bioavailable testosterone concentrations and neuropsychological testing were assessed using Spearman rank correlation. Overall, bioavailable testosterone was not an important determinant of cognitive, psychological, or sexual functioning or of quality of life. The implications for future studies involving testosterone replacement therapy are discussed.


Subject(s)
Cognition/drug effects , Hypogonadism/drug therapy , Quality of Life , Sexual Behavior/psychology , Testosterone/pharmacology , Testosterone/therapeutic use , Aged , Aging/physiology , Biological Availability , Humans , Middle Aged
11.
Cancer Treat Rev ; 27(3): 181-5, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11417969

ABSTRACT

Newer markers of bone formation and bone resorption are now available. Alone these new markers do not appear to be useful to diagnose metastatic bone disease. Several markers appear to be of prognostic importance and correlate with the extent of tumour in the skeleton. Serial monitoring of bone markers may be useful to monitor the efficacy of bisphosphonate and/or systemic therapy of both lytic and blastic bone metastases.


Subject(s)
Bone Development , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Bone Resorption/metabolism , Biomarkers , Humans , Prognosis
12.
Angew Chem Int Ed Engl ; 40(16): 3069-71, 2001.
Article in English | MEDLINE | ID: mdl-12203652

ABSTRACT

Lattices of single polystyrene particles were constructed by using a combinatorial approach to analyze particle pattern recognition properties. Dip-pen nanolithography was used to generate chemical templates of 16-thiohexadecanoic acid on a gold surface to study the two-dimensional assembly of amine- and amidine-modified particles.

13.
Angew Chem Int Ed Engl ; 40(16): 3071-3, 2001.
Article in English | MEDLINE | ID: mdl-12203653

ABSTRACT

Nanoscale construction work with DNA: Dip-pen nanolithography (DPN) is used to generate nanostructures which can be subsequently functionalized with oligonucleotides a' and b' and used to assemble, in an orthogonal manner, gold nanoparticles (a, b in scheme) functionalized with sequences complementary to the DPN-generated structures.

14.
J Steroid Biochem Mol Biol ; 79(1-5): 157-64, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11850220

ABSTRACT

Aromatase is expressed in both normal and malignant breast tissues. Aromatase activity in the breast varies over a wide range. Our previous studies have demonstrated that in situ aromatization contributes to the estrogen content of breast tumors to a major extent. Consequently, alterations of aromatase activity could serve as a major determinant of tissue estradiol content. However, the mechanisms and extent of aromatase regulation in breast tissues have not been fully established. We have observed an inverse correlation between tumor aromatase activity and estrogen content in nude mice bearing xenografts of MCF-7 cells transfected with the aromatase gene. To investigate the potential role of estrogen in aromatase regulation in the breast, studies were carried out in an in vitro model. In this model, MCF-7 cells were cultured long term in estrogen-deprived medium and called by the acronym, LTED cells. We found that long-term estrogen deprivation enhanced aromatase activity by 3-4-fold when compared to the wild-type MCF-7 cells. Re-exposure of LTED cells to estrogen reduced aromatase activity to the levels of the wild-type MCF-7 cells. We also measured aromatase activity in 101 frozen breast carcinoma specimens and compared tumor aromatase activities in pre-menopausal patients versus post-menopausal patients and in post-menopausal patients with or without hormone replacement therapy (HRT). Although statistically not significant, there was a trend paralleling that observed in the in vitro studies. Aromatase activity was higher in breast cancer tissues from the patients with lower circulating estrogen levels. Our data suggest that estrogen may be involved in the regulation of aromatase activity in breast tissues.


Subject(s)
Aromatase/metabolism , Breast/metabolism , Estrogens/metabolism , Animals , Breast/enzymology , Breast Neoplasms/enzymology , Breast Neoplasms/metabolism , Estradiol/metabolism , Estradiol/pharmacology , Female , Humans , Mice , Mice, Nude , Neoplasm Transplantation , Neoplasms, Hormone-Dependent/enzymology , Neoplasms, Hormone-Dependent/metabolism , Receptors, Estrogen/metabolism , Transplantation, Heterologous , Tumor Cells, Cultured
15.
Anal Chem ; 72(22): 5535-41, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11101228

ABSTRACT

Using a fluorescence-based method, we have determined the number of thiol-derivatized single-stranded oligonucleotides bound to gold nanoparticles and their extent of hybridization with complementary oligonucleotides in solution. Oligonucleotide surface coverages of hexanethiol 12-mer oligonucleotides on gold nanoparticles (34 +/- 1 pmol/cm2) were significantly higher than on planar gold thin films (18 +/- 3 pmol/cm2), while the percentage of hybridizable strands on the gold nanoparticles (1.3 +/- 0.3 pmol/cm2, 4%) was lower than for gold thin films (6 +/- 2 pmol/cm2, 33%). A gradual increase in electrolyte concentration over the course of oligonucleotide deposition significantly increases surface coverage and consequently particle stability. In addition, oligonucleotide spacer sequences improve the hybridization efficiency of oligonucleotide-modified nanoparticles from approximately 4 to 44%. The surface coverage of recognition strands can be tailored using coadsorbed diluent oligonucleotides. This provides a means of indirectly controlling the average number of hybridized strands per nanoparticle. The work presented here has important implications with regard to understanding interactions between modified oligonucleotides and metal nanoparticles, as well as optimizing the sensitivity of gold nanoparticle-based oligonucleotide detection methods.


Subject(s)
Gold/chemistry , Nucleic Acid Hybridization , Oligonucleotides/chemistry , Spectrometry, Fluorescence/methods , Particle Size , Surface Properties
16.
Am J Physiol Cell Physiol ; 279(3): C709-16, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10942721

ABSTRACT

To address the involvement of the calpain system in both basal and silica-induced nuclear factor (NF)-kappaB activation, several human bronchial epithelial cell lines were established in which an intracellular inhibitor of calpain, calpastatin, was stably expressed. Reduced basal and silica-induced inhibitor (IkappaBalpha) degradation and NF-kappaB activation were observed in cells stably overexpressing calpastatin. In addition, the cells in which calpain was constitutively inhibited by the overexpression of calpastatin exhibited a notable morphological change. Whereas empty vector-transfected cells displayed a morphology indistinguishable from that of parental cells, cells overexpressing calpastatin exhibited a mosaic morphological change with reduced formation of lamella 30 min after the cells were seeded. Genefilter microarray experiments, in which 3,965 human genes can be evaluated for their expression at the same time, showed that calpastatin downregulated genes encoding several membrane-associated proteins or nuclear proteins and upregulated genes of collagen alpha2, DAZ, and mitochondrial capsule selenoprotein. These results suggest that, in addition to their proteolytic activities on cytoskeletal proteins and other cellular regulatory proteins, calpain-calpastatin systems can also affect the expression levels of genes encoding structural or regulatory proteins.


Subject(s)
Calcium-Binding Proteins/pharmacology , Gene Expression/drug effects , NF-kappa B/physiology , Adrenergic beta-Agonists/pharmacology , Bronchi/cytology , Bronchi/metabolism , Calcium-Binding Proteins/genetics , Calcium-Binding Proteins/metabolism , Cell Line , Epithelial Cells/cytology , Epithelial Cells/metabolism , Humans , I-kappa B Proteins/metabolism , NF-kappa B/drug effects , Transfection
17.
Cancer ; 88(12 Suppl): 2919-26, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10898335

ABSTRACT

BACKGROUND: Skeletal metastases are common occurrences in patients with malignancies such as breast and prostate carcinoma, but they are difficult to diagnose nonradiologically, and treatment is difficult to follow clinically. Recent developments suggest that biochemical markers of bone remodeling, such as the bone collagen breakdown product N-telopeptide and the bone formation marker known as bone specific alkaline phosphatase, hold great promise as clinical tools for the management of patients with metastatic bone disease. METHODS: Serum levels of the bone formation marker known as bone specific alkaline phosphatase (BAP), along with serum levels of the bone collagen breakdown product carboxyterminal telopeptide of Type I collagen (ICTP) and urine levels of pyridinoline (PYD), deoxypridinoline (DPD), and N-telopeptide (NTx), were measured in a large cohort of patients with newly diagnosed or progressive cancer of the breast, prostate, lung, and other sites. Bone marker levels were correlated with the presence or absence of bone scan-documented metastases; metastatic disease extension in terms of the number of skeletal sites involved; and the type of lesion, whether blastic or lytic. Sites examined included the pelvis, spine, skull, ribs, and long bones. RESULTS: All of the bone markers examined, including BAP and NTx, were abnormally elevated in a high proportion of patients with confirmed metastases to bone. Urine NTx levels and bone specific alkaline phosphatase were significantly correlated with the number of skeletal sites involved, and a significant correlation between marker level and extent of skeletal involvement was also observed. In addition, both markers were higher in patients with a blastic disease presentation than in patients with osteolytic lesions. CONCLUSIONS: Biochemical markers of bone resorption and bone formation are abnormally raised in the blood and urine of patients with metastatic bone disease. Markers of bone collagen breakdown, such as N-telopeptide, as well as markers of osteoblast function, such as bone specific alkaline phosphatase, appear to be of use in assessing and managing patients with malignancies that metastasize to bone. In this study, both NTx and BAP showed a significant correlation with both the presence of bone metastases and the extent of skeletal involvement. Biochemical markers of bone remodeling can also be used to guide decision making regarding the treatment of metastatic bone disease and to determine the effectiveness of therapy for patients with cancer to bone whose broad-based symptoms make it difficult to discern true response to therapy.


Subject(s)
Bone Neoplasms/diagnosis , Bone Neoplasms/secondary , Alkaline Phosphatase/metabolism , Biomarkers , Bone Development , Bone Resorption/metabolism , Humans , Hydroxyproline/analysis
18.
J Clin Endocrinol Metab ; 85(3): 1021-5, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10720033

ABSTRACT

The development of the reproductive axis is thought to be a gradual process, but our understanding of the complex endocrine changes that accompany the transition from premenarche to reproductive life in women has been hampered by the paucity of longitudinal studies. We studied 112 premenarchal Caucasian females at 6-month intervals over 4 yr and obtained a detailed reproductive and dietary history. We quantified reproductive hormones in 24-h urine collections as a measure of daily output and measured body composition biometrically and with the use of dual energy x-ray absortiometry scans. The percent body fat did not change appreciably in the study period (range, 21-24%) and was unrelated to menarche. Sex steroid and gonadotropin levels changed exponentially in the year approaching menarche. FSH levels peaked at menarche and then progressively declined thereafter. Estradiol output increased rapidly in the year approaching menarche and then plateaued thereafter. The frequency of menstrual bleeding increased rapidly and plateaued at 1 yr postmenarche. At 1 yr, 65% of these adolescent women had established a pattern of 10 or more menstrual episodes/yr, and by 3 yr postmenarche this figure exceeded 90%. There were no significant changes in dietary intake of protein, carbohydrate, or fat in the same period. Menarche occurs as a result of rapid maturation of the reproductive axis and heralds the reestablishment of a negative sex steroid feedback loop that parallels the adult threshold. These events appear to develop independent of changes in body composition and diet, but may reflect the improved nutrition and socioeconomic status of the late 20th century.


Subject(s)
Body Composition/physiology , Menarche/physiology , Reproduction/physiology , Sexual Maturation/physiology , Adipose Tissue/physiology , Adolescent , Body Mass Index , Breast/growth & development , Diet , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Humans , Luteinizing Hormone/urine , Menstruation/physiology , Reference Values , Testosterone/urine
19.
Clin Cancer Res ; 5(11): 3438-44, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10589756

ABSTRACT

DFMO (alpha-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis. DFMO has been shown to have antiproliferative effects against several human cancers, and some studies have suggested that DFMO may have pro-apoptotic and anti-invasive properties as well. DFMO is well tolerated with minimal toxicity but has been associated with ototoxicity with prolonged daily administration. We conducted a Phase I/II tolerability, pharmacokinetic, and efficacy study of high-dose DFMO in metastatic breast cancer patients. Twenty-one patients were treated with 4800 mg of DFMO p.o. three times a day for 14 days, followed by a 2-week drug holiday on a 28-day cycle. Urinary polyamine and blood DFMO levels were measured at multiple time points during therapy. High-dose DFMO was well tolerated, and no clinically significant ototoxicity was noted. No patient achieved an objective antitumor response; however, one patient with heavily pretreated liver metastases has achieved stable disease for 18 months to date on DFMO. Putrescine, spermine, and spermidine urinary levels were suppressed with DFMO treatment and remained low during the 2-week drug holiday. High-dose DFMO on a schedule of 2 weeks on treatment followed by 2 weeks off is well tolerated, is not associated with ototoxicity, and leads to sustained suppression of urinary polyamine levels. Although not an active cytotoxic agent for metastatic breast cancer, the intriguing prolonged growth arrest of liver metastases in one patient highlights the potential clinical growth inhibitory properties of DFMO. We believe that DFMO is worthy of study as adjuvant therapy in primary breast cancer patients and as a chemopreventive agent.


Subject(s)
Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Eflornithine/therapeutic use , Polyamines/urine , Adult , Aged , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacokinetics , Breast Neoplasms/pathology , Eflornithine/adverse effects , Eflornithine/pharmacokinetics , Female , Humans , Middle Aged , Neoplasm Staging , Putrescine/urine , Receptors, Estrogen/analysis , Spermidine/urine , Spermine/urine , Time Factors
20.
J Adolesc Health ; 25(6): 379-81, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10608577

ABSTRACT

We studied 49 boys and girls with delayed physical sexual maturation during treatment with sex steroids. We found significant agreements, but also some disagreements between physicians' and subjects' Tanner sexual maturity ratings. We found neither effects of treatment with sex steroids nor gender differences, comparing ratings between physicians and patients.


Subject(s)
Puberty, Delayed/physiopathology , Self Concept , Sexual Maturation , Adolescent , Adult , Androgens/therapeutic use , Child , Double-Blind Method , Female , Humans , Male , Observer Variation , Sex Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...